Urge your members of Congress to support continued medical research funding
The American Society of Hematology (ASH) is pleased to recognize the following trainees with the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow at the 59th ASH Annual Meeting December 9-12 in Atlanta.
The American Society of Hematology, the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of three new members to its Executive Committee for terms beginning after the 2017 ASH Annual Meeting December 9-12 in Atlanta.
The drug hydroxyurea does not appear to increase the risk of malaria infection in patients with sickle cell anemia who live in malaria-endemic regions, according to a study published online today in Blood.
Norman “Ned” Sharpless, MD was sworn in today as the director of the National Cancer Institute. The NCI supports research and training initiatives to better understand, diagnose, treat, and cure cancers. A hematologist and ASH member, Dr. Sharpless takes over for Douglas Lowy, MD, who has led the Institute as acting director since 2015.
American Society of Hematology (ASH) President Kenneth C. Anderson, MD, of the Dana-Farber Cancer Institute, issued the following statement in response to the Administration’s decision to end cost sharing reduction (CSR) payments to insurers.
ASH announced the names of five investigators whose research has been awarded $150,000 through the ASH Bridge Grant Program.
New data indicates that an investigational treatment that mimics a key clotting enzyme is effective, safe, and may one day eliminate the need for blood products for people with the rare, life-threatening blood disease hereditary thrombotic thrombocytopenic purpura.
ASH today announced the names of 25 hematologists and medical professionals from developing countries selected to participate in the 2017 ASH Visitor Training Program (VTP). Participants will receive up to 12 weeks of specialized hematology training at host institutions in many different parts of the world.
ASH's President issued this response to today's approval by the U.S. FDA of the first chimeric antigen receptor (CAR) T-cell therapy for the treatment of children with relapsed/treatment-resistant CD-19 positive acute lymphocytic leukemia (ALL).
The American Society of Hematology will honor Betty S. Pace, MD, of Augusta University with the inaugural ASH Award for Leadership in Promoting Diversity for her extraordinary commitment to diversity and inclusion in hematology.
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology